Physician profile
Jayashri Bhaskar
NPI 1083801898
$6,706.84
in general payments reported to CMS, 2019-2025
19 companies · $642 in 2025
The $642 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,561 · 2020: $424 · 2021: $495 · 2022: $2,900 · 2023: $161 · 2024: $523 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,519.12 | 2022 | |
| Ethicon INC. | $1,198.30 | 2020-2024 | Monarch Platform |
| Covidien Lp | $929.61 | 2019 | |
| Glaxosmithkline, LLC. | $899.69 | 2019-2025 | Nucala |
| Intuitive Surgical, INC. | $368.03 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $334.21 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $294.69 | 2021-2025 | |
| Amgen INC. | $242.80 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.67 | 2019-2022 | |
| Insmed, INC. | $169.34 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $155.14 | 2021-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $89.66 | 2019-2020 | |
| Grifols USA, LLC | $63.95 | 2022-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $48.94 | 2019-2020 | |
| Pfizer INC. | $44.33 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $33.56 | 2025 | Smartvest |
| Merck Sharp & Dohme LLC | $33.25 | 2019 | |
| Verona Pharma, INC. | $29.77 | 2025 | Ohtuvayre |
| Olympus America INC. | $27.78 | 2024 | Spin Vision Video Processor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayashri Bhaskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.